Overview Dividends

(HOLX) Hologic - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4364401012

Diagnostics, Imaging, Surgery, Skeletal

EPS (Earnings per Share)

EPS Growth (3y CAGR): 2.00%
EPS Trend (3y Corr): 44.5%

Last SUE: 1.57σ
Qual. Beats: 2

Revenue

Revenue Growth (3y CAGR): -0.84%
Revenue Trend (3y Corr): 6.9%

Last SUE: 1.79σ
Qual. Beats: 2

Risk via 10d forecast
Volatility	20.0%
Value at Risk 5%th	30.9%
Relative Tail Risk	-6.17%

Reward TTM
Sharpe Ratio	-0.21
Alpha	-13.14

Character TTM
Hurst Exponent	0.406
Beta	0.320
Beta Downside	0.291

Drawdowns 3y
Max DD	39.85%
Mean DD	15.49%
Median DD	15.11%

Description: HOLX Hologic October 30, 2025

Hologic, Inc. (NASDAQ: HOLX) develops, manufactures, and markets diagnostics, medical imaging, and surgical solutions focused on women’s health, operating through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The firm’s portfolio includes Aptima molecular assays (viral load, bacterial vaginosis, SARS-CoV-2), ThinPrep cytology systems, 3-D digital mammography and related breast-cancer tools, as well as hysteroscopic and orthopedic devices such as MyoSure, NovaSure, and the Horizon DXA scanner.

Key performance indicators from the most recent fiscal year (FY 2023) show total revenue of approximately $5.0 billion, with the Diagnostics segment contributing roughly 55 % of sales and delivering a 14 % operating margin-both above the median for the health-care equipment sub-industry. The Breast Health segment grew 7 % YoY, driven by continued adoption of 3-D mammography, while the GYN Surgical line posted a 5 % increase, reflecting expanding minimally invasive procedures in outpatient settings.

Sector-wide, two macro drivers underpin Hologic’s growth outlook: (1) an aging female population that raises demand for bone-density (DXA) and breast-cancer screening services, and (2) sustained reimbursement pressure on diagnostic assays, which creates a pricing-discipline environment but also incentivizes higher-value, multiplex test platforms. A caveat is that Hologic’s reliance on U.S. Medicare/Medicaid reimbursement rates introduces regulatory-policy uncertainty that could affect future margins.

For a deeper quantitative assessment, you may find ValueRay’s analyst platform useful for drilling into HOLX’s financial metrics and peer comparisons.

HOLX Stock Overview

Market Cap in USD	16,494m
Sub-Industry	Health Care Equipment
IPO / Inception	1990-06-21
Return 12m vs S&P 500	-16.9%
Analyst Rating	3.45 of 5

HOLX Dividends

Currently no dividends paid

HOLX Growth Ratios

Metric	Value
CAGR 3y	-0.10%
CAGR/Max DD Calmar Ratio	0.00
CAGR/Mean DD Pain Ratio	-0.01
Current Volume	3020.5k
Average Volume	3799.2k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (565.8m TTM) > 0 and > 6% of Revenue (6% = 246.0m TTM)

FCFTA 0.11 (>2.0%) and ΔFCFTA -0.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 59.97% (prev 69.13%; Δ -9.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.07b > Net Income 565.8m (YES >=105%, WARN >=100%)

Net Debt (787.3m) to EBITDA (1.08b) ratio: 0.73 <= 3.0 (WARN <= 3.5)

Current Ratio 3.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (225.7m) change vs 12m ago -4.34% (target <= -2.0% for YES)

Gross Margin 53.01% (prev 55.78%; Δ -2.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 45.66% (prev 44.02%; Δ 1.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.95 (EBITDA TTM 1.08b / Interest Expense TTM 98.1m) >= 6 (WARN >= 3)

Altman Z'' 4.44

(A) 0.28 = (Total Current Assets 3.42b - Total Current Liabilities 962.5m) / Total Assets 8.81b

(B) 0.37 = Retained Earnings (Balance) 3.22b / Total Assets 8.81b

(D) 0.79 = Book Value of Equity 3.14b / Total Liabilities 3.96b

Total Rating: 4.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 70.86

1. Piotroski 6.0pt = 1.0

2. FCF Yield 5.48% = 2.74

3. FCF Margin 22.89% = 5.72

4. Debt/Equity 0.52 = 2.37

5. Debt/Ebitda 0.73 = 2.10

6. ROIC - WACC (= 2.56)% = 3.20

7. RoE 11.86% = 0.99

8. Rev. Trend 6.86% = 0.51

9. EPS Trend 44.52% = 2.23

What is the price of HOLX shares?

As of November 20, 2025, the stock is trading at USD 74.17 with a total of 3,020,520 shares traded.
Over the past week, the price has changed by -0.52%, over one month by +3.20%, over three months by +9.36% and over the past year by -5.60%.

Is HOLX a buy, sell or hold?

Hologic has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold HOLX.

Strong Buy: 3
Buy: 3
Hold: 14
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the HOLX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	76.2	2.7%
Analysts Target Price	76.2	2.7%
ValueRay Target Price	74.2	-0%

HOLX Fundamental Data Overview November 20, 2025

Market Cap USD = 16.49b (16.49b USD * 1.0 USD.USD)
P/E Trailing = 29.7631
P/E Forward = 16.2338
P/S = 4.0225
P/B = 3.2689
P/EG = 1.6387
Beta = 0.705
Revenue TTM = 4.10b USD
EBIT TTM = 779.5m USD
EBITDA TTM = 1.08b USD
Long Term Debt = 2.51b USD (from longTermDebt, two quarters ago)
Short Term Debt = 3.40m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 787.3m USD (from netDebt column, last quarter)
Enterprise Value = 17.14b USD (16.49b + Debt 2.52b - CCE 1.88b)
Interest Coverage Ratio = 7.95 (Ebit TTM 779.5m / Interest Expense TTM 98.1m)
FCF Yield = 5.48% (FCF TTM 938.7m / Enterprise Value 17.14b)
FCF Margin = 22.89% (FCF TTM 938.7m / Revenue TTM 4.10b)
Net Margin = 13.80% (Net Income TTM 565.8m / Revenue TTM 4.10b)
Gross Margin = 53.01% ((Revenue TTM 4.10b - Cost of Revenue TTM 1.93b) / Revenue TTM)
Gross Margin QoQ = 60.90% (prev 56.32%)
Tobins Q-Ratio = 1.95 (Enterprise Value 17.14b / Total Assets 8.81b)
Interest Expense / Debt = 0.38% (Interest Expense 9.60m / Debt 2.52b)
Taxrate = 17.63% (40.1m / 227.4m)
NOPAT = 642.0m (EBIT 779.5m * (1 - 17.63%))
Current Ratio = 3.55 (Total Current Assets 3.42b / Total Current Liabilities 962.5m)
Debt / Equity = 0.52 (Debt 2.52b / totalStockholderEquity, last quarter 4.84b)
Debt / EBITDA = 0.73 (Net Debt 787.3m / EBITDA 1.08b)
Debt / FCF = 0.84 (Net Debt 787.3m / FCF TTM 938.7m)
Total Stockholder Equity = 4.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.43% (Net Income 565.8m / Total Assets 8.81b)
RoE = 11.86% (Net Income TTM 565.8m / Total Stockholder Equity 4.77b)
RoCE = 10.71% (EBIT 779.5m / Capital Employed (Equity 4.77b + L.T.Debt 2.51b))
RoIC = 8.84% (NOPAT 642.0m / Invested Capital 7.26b)
WACC = 6.28% (E(16.49b)/V(19.02b) * Re(7.19%) + D(2.52b)/V(19.02b) * Rd(0.38%) * (1-Tc(0.18)))
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.06%
[DCF Debug] Terminal Value 77.27% ; FCFE base≈973.0m ; Y1≈910.0m ; Y5≈844.4m
Fair Price DCF = 68.00 (DCF Value 15.14b / Shares Outstanding 222.6m; 5y FCF grow -8.26% → 3.0% )
EPS Correlation: 44.52 | EPS CAGR: 2.00% | SUE: 1.57 | # QB: 2
Revenue Correlation: 6.86 | Revenue CAGR: -0.84% | SUE: 1.79 | # QB: 2

Additional Sources for HOLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle